Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $148.0 million.

  • Myriad Genetics' Total Current Liabilities fell 4.08% to $148.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.0 million, marking a year-over-year decrease of 4.08%. This contributed to the annual value of $164.1 million for FY2024, which is 5.26% up from last year.
  • As of Q3 2025, Myriad Genetics' Total Current Liabilities stood at $148.0 million, which was down 25.96% from $199.9 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Total Current Liabilities peaked at $271.0 million during Q2 2021, and registered a low of $119.7 million during Q2 2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $154.3 million (2024), whereas its average is $167.5 million.
  • In the last 5 years, Myriad Genetics' Total Current Liabilities tumbled by 55.83% in 2022 and then spiked by 84.71% in 2023.
  • Myriad Genetics' Total Current Liabilities (Quarterly) stood at $204.3 million in 2021, then tumbled by 32.84% to $137.2 million in 2022, then rose by 13.63% to $155.9 million in 2023, then increased by 5.26% to $164.1 million in 2024, then decreased by 4.08% to $148.0 million in 2025.
  • Its Total Current Liabilities stands at $148.0 million for Q3 2025, versus $199.9 million for Q2 2025 and $151.1 million for Q1 2025.